| Year |
Citation |
Score |
| 2023 |
Rasool RU, O'Connor CM, Das CK, Alhusayan M, Verma BK, Islam S, Frohner IE, Deng Q, Mitchell-Velasquez E, Sangodkar J, Ahmed A, Linauer S, Mudrak I, Rainey J, Zawacki KP, et al. Loss of LCMT1 and biased protein phosphatase 2A heterotrimerization drive prostate cancer progression and therapy resistance. Nature Communications. 14: 5253. PMID 37644036 DOI: 10.1038/s41467-023-40760-6 |
0.625 |
|
| 2021 |
O'Connor CM, Taylor SE, Miller KM, Hurst L, Haanen TJ, Suhan TK, Zawacki KP, Noto FK, Trako J, Mohan A, Sangodkar J, Zamarin D, DiFeo A, Narla G. Targeting ribonucleotide reductase induces synthetic lethality in PP2A-deficient uterine serous carcinoma. Cancer Research. PMID 34921012 DOI: 10.1158/0008-5472.CAN-21-1987 |
0.628 |
|
| 2021 |
Scarpa M, Singh P, Bailey CM, Lee JK, Kapoor S, Lapidus RG, Niyongere S, Sangodkar J, Wang Y, Perrotti D, Narla G, Baer MR. PP2A-activating drugs enhance FLT3 inhibitor efficacy through AKT inhibition-dependent GSK-3β-mediated c-Myc and Pim-1 proteasomal degradation. Molecular Cancer Therapeutics. PMID 33568357 DOI: 10.1158/1535-7163.MCT-20-0663 |
0.607 |
|
| 2020 |
Noto FK, Sangodkar J, Adedeji BT, Moody S, McClain CB, Tong M, Ostertag E, Crawford J, Gao X, Hurst L, O'Connor CM, Hanson EN, Izadmehr S, Tohmé R, Narla J, et al. The SRG rat, a Sprague-Dawley Rag2/Il2rg double-knockout validated for human tumor oncology studies. Plos One. 15: e0240169. PMID 33027304 DOI: 10.1371/journal.pone.0240169 |
0.589 |
|
| 2020 |
Coles GL, Cristea S, Webber JT, Levin RS, Moss SM, He A, Sangodkar J, Hwang YC, Arand J, Drainas AP, Mooney NA, Demeter J, Spradlin JN, Mauch B, Le V, et al. Unbiased Proteomic Profiling Uncovers a Targetable GNAS/PKA/PP2A Axis in Small Cell Lung Cancer Stem Cells. Cancer Cell. PMID 32531271 DOI: 10.1016/J.Ccell.2020.05.003 |
0.699 |
|
| 2019 |
Farrington CC, Yuan E, Mazhar S, Izadmehr S, Hurst L, Allen-Petersen BL, Janghorban M, Chung E, Wolczanski G, Galsky M, Sears R, Sangodkar J, Narla G. Protein phosphatase 2A activation as a therapeutic strategy for managing MYC-driven cancers. The Journal of Biological Chemistry. PMID 31822503 DOI: 10.1074/Jbc.Ra119.011443 |
0.733 |
|
| 2019 |
O'Connor CM, Leonard D, Wiredja D, Avelar RA, Wang Z, Schlatzer D, Bryson B, Tokala E, Taylor SE, Upadhyay A, Sangodkar J, Gingras AC, Westermarck J, Xu W, DiFeo A, et al. Inactivation of PP2A by a recurrent mutation drives resistance to MEK inhibitors. Oncogene. PMID 31541192 DOI: 10.1038/S41388-019-1012-2 |
0.664 |
|
| 2019 |
Taylor SE, O'Connor CM, Wang Z, Shen G, Song H, Leonard D, Sangodkar J, LaVasseur C, Avril S, Waggoner S, Zanotti K, Armstrong AJ, Nagel C, Resnick K, Singh S, et al. The highly recurrent PP2A Aα-subunit mutation P179R alters protein structure and impairs PP2A enzyme function to promote endometrial tumorigenesis. Cancer Research. PMID 31142515 DOI: 10.1158/0008-5472.Can-19-0218 |
0.636 |
|
| 2019 |
Tohmé R, Izadmehr S, Gandhe S, Tabaro G, Vallabhaneni S, Thomas A, Vasireddi N, Dhawan NS, Ma'ayan A, Sharma N, Galsky MD, Ohlmeyer M, Sangodkar J, Narla G. Direct activation of PP2A for the treatment of tyrosine kinase inhibitor-resistant lung adenocarcinoma. Jci Insight. 4. PMID 30830869 DOI: 10.1172/Jci.Insight.125693 |
0.696 |
|
| 2019 |
Mazhar S, Taylor SE, Sangodkar J, Narla G. Targeting PP2A in cancer: Combination therapies. Biochimica Et Biophysica Acta. Molecular Cell Research. 1866: 51-63. PMID 30401535 DOI: 10.1016/J.Bbamcr.2018.08.020 |
0.718 |
|
| 2018 |
Noto FK, Adjan Steffey V, Tong M, Ravichandran K, Zhang W, Arey A, McClain CB, Ostertag E, Mazhar S, Sangodkar J, Difeo A, Crawford J, Narla G, Jamling TY. Sprague Dawley Rag2 null rats created from engineered spermatogonial stem cells are immunodeficient and permissive to human xenografts. Molecular Cancer Therapeutics. PMID 30206106 DOI: 10.1158/1535-7163.Mct-18-0156 |
0.632 |
|
| 2018 |
Kauko O, O'Connor CM, Kulesskiy E, Sangodkar J, Aakula A, Izadmehr S, Yetukuri L, Yadav B, Padzik A, Laajala TD, Haapaniemi P, Momeny M, Varila T, Ohlmeyer M, Aittokallio T, et al. PP2A inhibition is a druggable MEK inhibitor resistance mechanism in KRAS-mutant lung cancer cells. Science Translational Medicine. 10. PMID 30021885 DOI: 10.1126/Scitranslmed.Aaq1093 |
0.735 |
|
| 2018 |
Narla G, Sangodkar J, Ryder CB. The impact of phosphatases on proliferative and survival signaling in cancer. Cellular and Molecular Life Sciences : Cmls. PMID 29725697 DOI: 10.1007/S00018-018-2826-8 |
0.669 |
|
| 2018 |
McClinch K, A Avelar R, Callejas D, Izadmehr S, Wiredja D, Perl A, Sangodkar J, Kastrinsky DB, Schlatzer D, Cooper M, Kiselar J, Stachnik A, Yao S, Hoon D, McQuaid D, et al. Small molecule activators of protein phosphatase 2A for the treatment of castration-resistant prostate cancer. Cancer Research. PMID 29358171 DOI: 10.1158/0008-5472.Can-17-0123 |
0.69 |
|
| 2018 |
Wiredja DD, Liao P, Sangodkar J, Schlatzer D, Chance MR, Narla G. Abstract 2698: Phosphoproteomics-guided anticancer drug combination design with a novel small-molecule PP2A activator Cancer Research. 78: 2698-2698. DOI: 10.1158/1538-7445.Am2018-2698 |
0.7 |
|
| 2017 |
O'Connor CM, Perl A, Leonard D, Sangodkar J, Narla G. Therapeutic Targeting of PP2A. The International Journal of Biochemistry & Cell Biology. PMID 29107183 DOI: 10.1016/J.Biocel.2017.10.008 |
0.659 |
|
| 2017 |
Wiredja DD, Ayati M, Mazhar S, Sangodkar J, Maxwell S, Schlatzer D, Narla G, Koyutürk M, Chance MR. Phosphoproteomics Profiling of Non-Small Cell Lung Cancer Cells Treated with a Novel Phosphatase Activator. Proteomics. PMID 28961369 DOI: 10.1002/Pmic.201700214 |
0.707 |
|
| 2017 |
Sangodkar J, Perl A, Tohme R, Kiselar J, Kastrinsky DB, Zaware N, Izadmehr S, Mazhar S, Wiredja DD, O'Connor CM, Hoon D, Dhawan NS, Schlatzer D, Yao S, Leonard D, et al. Activation of tumor suppressor protein PP2A inhibits KRAS-driven tumor growth. The Journal of Clinical Investigation. PMID 28504649 DOI: 10.1172/Jci89548 |
0.758 |
|
| 2017 |
Tohme R, Sangodkar J, Kiselar J, Leonard D, O'Connor C, Gandhe S, Xu W, Brautigan D, Chance M, Ohlmeyer M, Narla G. Abstract 4173: Drug target mutations as a mechanism of acquired resistance to small molecules activators of protein phosphatase 2a Cancer Research. 77: 4173-4173. DOI: 10.1158/1538-7445.Am2017-4173 |
0.619 |
|
| 2016 |
Sangodkar J, Tohme R, Kiselar J, Izadmehr S, Hoon D, Mazhar S, Perl A, Wiredja D, Schlatzer D, Yao S, Kastrinsky D, Sharma N, Brautigan D, Chance M, Borczuk A, et al. Abstract 3865: Therapeutic activation of protein phosphatase 2A for the treatment of lung cancer Cancer Research. 76: 3865-3865. DOI: 10.1158/1538-7445.Am2016-3865 |
0.769 |
|
| 2015 |
Kastrinsky DB, Sangodkar J, Zaware N, McClinch K, Farrington CC, Giannini HM, Izadmehr S, Dhawan NS, Narla G, Ohlmeyer M. Corrigendum to "Reengineered tricyclic anti-cancer agents" [Bioorg. Med. Chem. 23 (2015) 6528-6534]. Bioorganic & Medicinal Chemistry. 23: 7487. PMID 28290285 DOI: 10.1016/J.Bmc.2015.11.002 |
0.629 |
|
| 2015 |
Sangodkar J, Farrington C, McClinch K, Galsky MD, Kastrinsky DB, Narla G. All roads lead to PP2A: Exploiting the therapeutic potential of this phosphatase. The Febs Journal. PMID 26507691 DOI: 10.1111/Febs.13573 |
0.691 |
|
| 2015 |
Kastrinsky DB, Sangodkar J, Zaware N, Izadmehr S, Dhawan NS, Narla G, Ohlmeyer M. Reengineered tricyclic anti-cancer agents. Bioorganic & Medicinal Chemistry. 23: 6528-34. PMID 26372073 DOI: 10.1016/J.Bmc.2015.07.007 |
0.682 |
|
| 2015 |
Sangodkar J, Izadmehr S, Mahzar S, Hoon D, Yao S, Kastrinsky D, Schlatzer D, Sharma N, Borczuk AC, Ohlmeyer M, Ioannou Y, Narla G. Abstract 5329: Development of small molecule activators of protein phosphatase 2A for the treatment of lung cancer Cancer Research. 75: 5329-5329. DOI: 10.1158/1538-7445.Am2015-5329 |
0.768 |
|
| 2015 |
Sangodkar J, McQuaid D, Kisselar J, Brautigan D, Chance M, Ohlmeyer M, Kastrinsky D, Ioannou Y, Narla G. Abstract B124: Drugging the undruggable: development of small molecule activators of protein phosphatase 2A for cancer treatment Molecular Cancer Therapeutics. 14. DOI: 10.1158/1535-7163.Targ-15-B124 |
0.778 |
|
| 2014 |
Yuen T, Stachnik A, Iqbal J, Sgobba M, Gupta Y, Lu P, Colaianni G, Ji Y, Zhu LL, Kim SM, Li J, Liu P, Izadmehr S, Sangodkar J, Bailey J, et al. Bisphosphonates inactivate human EGFRs to exert antitumor actions. Proceedings of the National Academy of Sciences of the United States of America. 111: 17989-94. PMID 25453081 DOI: 10.1073/Pnas.1421410111 |
0.724 |
|
| 2014 |
Stachnik A, Yuen T, Iqbal J, Sgobba M, Gupta Y, Lu P, Colaianni G, Ji Y, Zhu LL, Kim SM, Li J, Liu P, Izadmehr S, Sangodkar J, Scherer T, et al. Repurposing of bisphosphonates for the prevention and therapy of nonsmall cell lung and breast cancer. Proceedings of the National Academy of Sciences of the United States of America. 111: 17995-8000. PMID 25453078 DOI: 10.1073/Pnas.1421422111 |
0.726 |
|
| 2014 |
Sangodkar J, Mazhar S, Wiredja D, Gokulrangan G, Schlatzer D, Kastrinsky D, Difeo A, Yao S, Izadmehr S, Sharma N, Ioannou Y, Ohlmeyer M, Narla G. Abstract A38: Therapeutic targeting of oncogenic KRAS signaling using a novel small molecule agonist of the PP2A tumor suppressor gene Molecular Cancer Research. 12. DOI: 10.1158/1557-3125.Rasonc14-A38 |
0.776 |
|
| 2014 |
Sangodkar J, Mazhar S, Kastrinsky D, Ohlmeyer M, Narla G. 486 Development of small molecule activators of protein phosphatase 2A for the treatment of lung cancer European Journal of Cancer. 50: 158-159. DOI: 10.1016/S0959-8049(14)70612-4 |
0.669 |
|
| 2013 |
Das TK, Sangodkar J, Negre N, Narla G, Cagan RL. Sin3a acts through a multi-gene module to regulate invasion in Drosophila and human tumors. Oncogene. 32: 3184-97. PMID 22890320 DOI: 10.1038/Onc.2012.326 |
0.669 |
|
| 2012 |
Sangodkar J, Dhawan NS, Melville H, Singh VJ, Yuan E, Rana H, Izadmehr S, Farrington C, Mazhar S, Katz S, Albano T, Arnovitz P, Okrent R, Ohlmeyer M, Galsky M, et al. Targeting the FOXO1/KLF6 axis regulates EGFR signaling and treatment response. The Journal of Clinical Investigation. 122: 2637-51. PMID 22653055 DOI: 10.1172/Jci62058 |
0.699 |
|
| 2012 |
Sangodkar J, Dhawan N, Melville H, Singh VJ, Farrington C, Yuan E, Rana H, Smith B, Gidwani V, Okrent R, Burstein D, Ohlmeyer M, Politi K, DiFeo A, Narla G. Abstract 1885: Targeting the FOXO1/KLF6 transcriptional network to modulate response to anti-EGFR based therapy Cancer Research. 72: 1885-1885. DOI: 10.1158/1538-7445.Am2012-1885 |
0.722 |
|
| 2011 |
Sangodkar J, Katz S, Melville H, Singh V, Dhawan N, DiFeo A, Narla G. Abstract 2899: Restoring sensitivity to anti-EGFR-based therapy in lung adenocarcinoma by downstream modulation of the FOXO1/KLF6 transcriptional network Cancer Research. 71: 2899-2899. DOI: 10.1158/1538-7445.Am2011-2899 |
0.732 |
|
| 2011 |
Dhawan N, Smith B, Sangodkar J, Gidwani V, Kastrinsky D, Ohlmeyer M, Narla G. Abstract A218: Simultaneous inhibition of both the PI3K-AKT and MAPK-ERK pathways using a single small molecule based approach for the treatment of advanced cancer. Molecular Cancer Therapeutics. 10. DOI: 10.1158/1535-7163.Targ-11-A218 |
0.708 |
|
| 2010 |
Sangodkar J, Katz S, Melville H, Narla G. Lung adenocarcinoma: lessons in translation from bench to bedside. The Mount Sinai Journal of Medicine, New York. 77: 597-605. PMID 21105123 DOI: 10.1002/Msj.20226 |
0.698 |
|
| 2010 |
Sangodkar J, Katz S, Albano T, Melville H, Burstein D, Politi K, Difeo A, Narla G. Abstract B41: Restoring sensitivity to anti-EGFR-based therapy in lung adenocarcinoma by downstream modulation of the FOXO1/KLF6 transcriptional network Clinical Cancer Research. 16. DOI: 10.1158/1078-0432.Tcmusa10-B41 |
0.705 |
|
| 2009 |
Difeo A, Huang F, Sangodkar J, Terzo EA, Leake D, Narla G, Martignetti JA. KLF6-SV1 is a novel antiapoptotic protein that targets the BH3-only protein NOXA for degradation and whose inhibition extends survival in an ovarian cancer model. Cancer Research. 69: 4733-41. PMID 19435908 DOI: 10.1158/0008-5472.Can-08-4282 |
0.673 |
|
| 2009 |
Sangodkar J, DiFeo A, Feld L, Bromberg R, Schwartz R, Huang F, Terzo EA, Choudhri A, Narla G. Targeted reduction of KLF6-SV1 restores chemotherapy sensitivity in resistant lung adenocarcinoma. Lung Cancer (Amsterdam, Netherlands). 66: 292-7. PMID 19328586 DOI: 10.1016/J.Lungcan.2009.02.014 |
0.707 |
|
| 2009 |
Sangodkar J, Shi J, DiFeo A, Schwartz R, Bromberg R, Choudhri A, McClinch K, Hatami R, Scheer E, Kremer-Tal S, Martignetti JA, Hui A, Leung WK, Friedman SL, Narla G. Functional role of the KLF6 tumour suppressor gene in gastric cancer. European Journal of Cancer (Oxford, England : 1990). 45: 666-76. PMID 19101139 DOI: 10.1016/J.Ejca.2008.11.009 |
0.75 |
|
| 2008 |
Narla G, DiFeo A, Fernandez Y, Dhanasekaran S, Huang F, Sangodkar J, Hod E, Leake D, Friedman SL, Hall SJ, Chinnaiyan AM, Gerald WL, Rubin MA, Martignetti JA. KLF6-SV1 overexpression accelerates human and mouse prostate cancer progression and metastasis. The Journal of Clinical Investigation. 118: 2711-21. PMID 18596922 DOI: 10.1172/Jci34780 |
0.648 |
|
| Show low-probability matches. |